MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Registration Number
- NCT00092690
- Lead Sponsor
- Organon and Co
- Brief Summary
This study is to assess the safety and efficacy of an investigational drug as compared to an approved drug to reduce specific cholesterol levels.
- Detailed Description
The duration of treatment is 6 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1902
Inclusion Criteria
- Elevated cholesterol
Exclusion Criteria
- Unstable medical conditions or significant heart problems within 3 months prior to first study visit.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Plasma LDL-C averaged across all doses after 6 weeks
- Secondary Outcome Measures
Name Time Method Plasma LDL-C for each dose; plasma HDL-C averaged across all doses